The use of «Polyoxidonium» contributes to a decrease in the number of cases of acute respiratory viral infections and COVID-19, as well as a milder course of the disease, if it does occur. This was stated by leading experts in the field of infectology, pediatrics and otolaryngology at the scientific conference Polyoxidonium Talks, dedicated to the experience of using the Russian drug.
Advertising . NPO PETROVAKS PHARM LLC. https://polyoxidonium.ru/ erir: 4CQwVszH9pSXM7uAprP
Influenza and SARS viruses, along with coronavirus, are quickly and easily transmitted, mainly by airborne droplets. Rospotrebnadzor recorded more than 60 thousand new cases of COVID-19, and the total number of cases of acute respiratory viral infections and influenza exceeded 1 million people.
Despite the wide spread of influenza, patients do not always take timely preventive and treatment measures, while complications such as pneumonia, lung tissue dysfunction and respiratory failure are of particular danger. In 2023, the Ministry of Health of the Russian Federation updated the clinical guidelines “Influenza in adults” to include the drug azoximer bromide (“Polyoxidonium®”). The drug helps to strengthen the barrier protection of mucous membranes from infections, increase the body's resistance to viruses, reduce inflammation and intoxication.
At a scientific conference held on February 11, scientists noted the extensive experience of using Polyoxidonium in clinical practice for the prevention and therapy of viral infections.
Academician of the Russian Academy of Sciences, infectiologist Alexander Gorelovshared the results of a large-scale meta-analysis of the use of Polyoxidonium in the prevention of COVID infection in adults: “During the coronavirus pandemic, doctors in the red zone who received Polyoxidonium® as a prophylaxis demonstrated greater resistance to infectious diseases and were diagnosed with COVID-19 3 times less than in the control group.”
Professor, MD Sergey Zyryanovadded that Polyoxidonium is able to increase the survival rate of severe patients with developed pneumonia by 50%, as well as reduce the need for mechanical ventilation.
Experts shared their experience of using the drug in children in the treatment of infectious and inflammatory diseases. As part of the largest study, scientists observed 900 children attending childcare facilities aged 3 to 10 years for 3 months. In the group taking the drug, ARVI was recorded in 25.66% of participants, and coronavirus infection in only 1%. At the same time, in the control group, the percentage of ARVI cases was 95.66%, and the proportion of cases of COVID-19 was 8%. In addition, when using «Polyoxidonium®» in the group with a prolonged prophylactic course, none of the participants fell ill with pneumonia, while in the control group, pneumonia was noted in 2.22% of cases of SARS.
Vera Vavilova, MD, Chairman of the regional branch of the public organization «Union of Pediatricians of Russia» in the Kemerovo region summarized: «When using «Polyoxidonium®», the study recorded a significant decrease in the number of cases of acute respiratory viral infections and COVID-19, compared with control group. The use of the drug contributes to a milder course of the disease and significantly reduces the risk of bacterial complications that require antibiotics, which is important for clinical use in children.”
Galina Nikiforova, MD, Professor, Department of Ear Diseases, throat and nose of the First Moscow State Medical University. THEM. Sechenova added that «Polyoxidonium» contributes to the normalization of immunity, not only immediately after treatment, but also for 3.5 months after its completion, which helps protect the body from infection.
For reference:
Polyoxidonium has been widely used in clinical practice in Russia and abroad for more than 25 years and is included in the list of Vital and Essential Drugs. In addition, it meets all EU regulatory requirements, is registered in Slovakia and included in European clinical guidelines for the treatment of coronavirus infection.